> top > docs > PMC:7200337 > spans > 99234-99542 > annotations

PMC:7200337 / 99234-99542 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T752 250-258 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T573 46-54 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1034 24-31 http://purl.obolibrary.org/obo/CLO_0009985 denotes focused
T1035 108-114 http://purl.obolibrary.org/obo/NCBITaxon_33208 denotes animal

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
3279 151-153 Gene denotes to Gene:6999
3280 72-74 Gene denotes to Gene:6999
3293 46-56 Species denotes SARS-CoV-2 Tax:2697049
3294 163-171 Species denotes patients Tax:9606
3299 101-104 Chemical denotes nAb
3301 154-162 Disease denotes infected MESH:D007239

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T582 0-308 Sentence denotes Similar studies are now focused on the use of SARS-CoV-2 or derivatives to generate highly effective nAb in animal models, which can be directly given to infected patients, and efforts are already underway with estimates of clinical trials of pooled antibody cocktails beginning in early summer by Regeneron.